Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia.
Anna HechtJulia MeyerFarid F ChehabKristie L WhiteKevin MagruderChristopher C DvorakMignon L LohElliot StieglitzPublished in: Pediatric blood & cancer (2019)
Despite the myelodysplastic nature of JMML, patients treated with pre-HCT therapy can achieve molecular remissions. These patients experienced a trend toward improved outcomes post-HCT. Importantly, molecular testing can be helpful to distinguish between responders and nonresponders and should become an integral part of clinical care.
Keyphrases
- end stage renal disease
- acute myeloid leukemia
- bone marrow
- healthcare
- chronic kidney disease
- newly diagnosed
- ejection fraction
- prognostic factors
- peritoneal dialysis
- type diabetes
- skeletal muscle
- patient reported outcomes
- quality improvement
- metabolic syndrome
- adipose tissue
- pain management
- signaling pathway
- smoking cessation